A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer

NCT07671339 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: ELI-002 7P
DRUG: Tislelizumab
DRUG: mFOLFIRINOX

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]